Is HIFU for Prostate Cancer Covered by Insurance?

Whether HIFU for prostate cancer is covered by insurance depends almost entirely on one question: are you being treated for cancer that came back after radiation, or is this your first treatment? Most health plans and Medicare cover high-intensity focused ultrasound when the disease has recurred after radiation therapy. For newly diagnosed, previously untreated prostate cancer, nearly every major carrier classifies HIFU as experimental and denies the claim. Total charges typically run between $18,000 and $30,000, so knowing which side of that line your case falls on has real financial consequences.

Why the Recurrent vs. Primary Distinction Matters

HIFU uses focused ultrasound energy to heat and destroy cancerous prostate tissue without incisions. Clinical evidence for using it as salvage therapy, meaning treatment after an initial round of radiation has failed, is substantially stronger than the evidence for using it instead of surgery or radiation at the outset. Insurers follow that evidence gap closely.

The National Comprehensive Cancer Network recommends HIFU only for treating localized, biopsy-confirmed recurrence after external beam radiation when there is no metastatic disease. A 2024 joint guideline from the American Urological Association, ASTRO, and SUO similarly endorses HIFU as a salvage option but not as a standard first-line treatment.1UnitedHealthcare. Prostate Surgeries and Interventions When insurers deny primary-treatment claims, this guideline consensus is what they cite. If your urologist is recommending HIFU as your initial treatment, the approval process will be harder and the odds of denial are higher.

Medicare Coverage for HIFU

Medicare has no National Coverage Determination for HIFU, so there is no single nationwide rule. Coverage is decided regionally by Medicare Administrative Contractors through Local Coverage Determinations.2Centers for Medicare & Medicaid Services. Local Coverage Determinations Each contractor weighs the clinical evidence and decides whether the procedure counts as reasonable and necessary in its jurisdiction.

Where coverage exists, it applies to recurrent prostate cancer after radiation, not primary treatment. A representative set of Medicare LCD criteria requires all of the following:

  • A recent transrectal ultrasound-guided biopsy confirming local cancer recurrence
  • Original clinical stage of T1 or T2, with no lymph node involvement
  • A recent prostate-specific antigen level under 10 ng/mL
  • No evidence of metastatic disease

These criteria come from a Local Coverage Article addressing HIFU for recurrent prostate cancer.3Providence Health Plan. Prostate – High Intensity Focused Ultrasound HIFU Medicare Only Because LCDs vary by region, the exact criteria in your area may differ. Your treatment facility’s billing office should know which MAC covers your region and whether a favorable LCD exists. If your contractor hasn’t issued one for HIFU, you’re asking for an exception rather than fitting into an established policy, and approval becomes substantially harder.

Where the Major Private Insurers Stand

The pattern across large private carriers is strikingly consistent: HIFU is covered for recurrent cancer after radiation failure, and treated as experimental or investigational for everything else.

Aetna

Aetna considers HIFU medically necessary for radio-recurrent prostate cancer in the absence of metastatic disease. For HIFU as a first treatment, Aetna explicitly classifies it as “experimental, investigational, or unproven.”4Aetna. High Intensity Focused Ultrasound That classification means a primary-treatment claim will almost certainly be denied under a standard Aetna plan.

Cigna

Cigna’s policy mirrors Aetna’s. HIFU is medically necessary only for recurrent localized prostate cancer after radiation failure, and only when the patient has a positive repeat biopsy showing local recurrence and no distant metastases. Cigna’s policy is blunt about everything else, stating that HIFU “is not medically necessary for ANY other indication including as an initial treatment for localized prostate cancer.”5Cigna. High Intensity Focused Ultrasound HIFU Medical Coverage Policy

UnitedHealthcare

UnitedHealthcare’s policy follows the 2024 AUA/ASTRO/SUO salvage guideline listing HIFU as an option for radiation-recurrent cancer. For primary treatment, UHC cites the AUA/ASTRO guidance that whole-gland or focal ablation “should not be recommended outside of a clinical trial.”1UnitedHealthcare. Prostate Surgeries and Interventions Expect first-line claims to be denied.

Blue Cross Blue Shield

BCBS affiliates set their own medical policies, so coverage details vary by state. Blue Cross Blue Shield of Michigan covers HIFU for local treatment of recurrent prostate cancer when the original clinical stage was T1 or T2, the current PSA is below 10 ng/mL, and primary treatment was radiation therapy.6Blue Cross Blue Shield of Michigan. Focal Treatments for Prostate Cancer Other affiliates may use slightly different thresholds, but the pattern holds. Request your specific affiliate’s medical policy document for focal prostate treatments before assuming anything about coverage.

TRICARE and VA Coverage

Coverage for military-connected patients is less clear-cut. TRICARE’s policy manual has historically excluded Category III CPT codes, the temporary codes assigned to emerging procedures, on the grounds that “clinical safety and efficacy or applicability to clinical practice has not been established.”7TRICARE Manuals. Category III Codes – Temporary Codes for Emerging Technology, Services and Procedures HIFU was originally billed under a Category III code, but the American Medical Association assigned it a permanent Category I code (55880) starting in 2021. That reclassification may have changed TRICARE’s position, though a definitive public policy update is not available. TRICARE beneficiaries should contact their regional contractor directly for a current coverage determination.

The VA health system has performed HIFU on veterans at some facilities. VA coverage decisions are made clinically rather than through the pre-authorization framework private insurers use, so eligibility turns largely on your treatment team’s recommendation.

What HIFU Costs

Even with coverage, you’ll likely owe a share of the bill. The two main components are the facility fee and the professional fee. The facility fee covers the ultrasound equipment and the outpatient surgical suite and typically runs $15,000 to $25,000. The professional fee pays the urologist performing and monitoring the ablation and usually falls between $3,000 and $5,000. Combined charges often land between $18,000 and $30,000.

If your insurer denies coverage, which is the likely outcome for primary treatment, you’re on the hook for the full amount. Many HIFU centers offer financing or will negotiate a cash-pay discount, so ask about both before scheduling. If the procedure is covered but applied to your deductible and coinsurance, your out-of-pocket share depends on your plan’s cost-sharing structure. Request a pre-treatment cost estimate from both the facility and the surgeon’s billing office.

Documentation to Have Ready

Getting a claim approved, or building the strongest possible case for an appeal, requires a specific set of records. Start gathering them before your urologist submits the pre-authorization request.

The procedure is billed under CPT code 55880, which describes transrectal ablation of malignant prostate tissue using HIFU. This code must be paired with ICD-10 diagnosis code C61 for malignant neoplasm of the prostate.4Aetna. High Intensity Focused Ultrasound Your urologist’s billing staff handles the coding, but confirm it’s right. A coding error can trigger an automatic denial that has nothing to do with medical necessity.

The clinical records your insurer will evaluate include:

  • A recent transrectal ultrasound-guided biopsy confirming the presence and grade of cancer. For salvage claims, the biopsy must specifically document local recurrence.
  • MRI reports showing the location and extent of the tumor. Multiparametric MRI has become the standard for HIFU treatment planning, and insurers expect to see it.
  • Recent and historical PSA levels. Most coverage criteria require a current PSA under 10 ng/mL.
  • Staging documentation establishing the clinical stage and showing no lymph node involvement or distant metastases.
  • Prior treatment records. For a recurrent-cancer claim, documentation of your original radiation therapy is what distinguishes a likely-approved salvage claim from a likely-denied primary one.

A letter of medical necessity from your urologist strengthens the pre-authorization request. The letter should map your clinical profile directly to the specific criteria in your insurer’s published medical policy. The more precisely the letter tracks those criteria, the faster the approval tends to go.

Pre-Authorization Timelines and Appeals

Your urologist’s office submits the pre-authorization request along with the clinical documentation. As of January 2026, Medicare Advantage plans must respond to standard prior authorization requests within seven calendar days. Marketplace plans generally have up to 15 days. Expedited requests, where a delay could jeopardize your health, must be decided within 72 hours across all plan types.8HealthCare.gov. Internal Appeals

What to Do After a Denial

A denial triggers your right to an internal appeal, a full review of the decision by the insurance company. You have 180 days from the denial notice to file. For services you haven’t yet received, which covers most HIFU pre-authorization denials, the insurer must complete the internal appeal within 30 days. For urgent situations, the decision must come within four business days.8HealthCare.gov. Internal Appeals

If the internal appeal fails, federal law gives you the right to an external review by an independent third party.9HealthCare.gov. How to Appeal an Insurance Company Decision The external reviewer is a physician who evaluates whether the treatment meets the standard of care for your diagnosis, and the insurer no longer has the final say. External review is particularly worth pursuing if your denial involved recurrent cancer, since the clinical guidelines supporting salvage therapy are strong. For primary-treatment denials, external review is still your right, but the odds are lower given the current guideline landscape.

Keep a written record of every interaction with your insurer: dates, names, reference numbers, and what was said. If the process reaches external review or you need to escalate to your state insurance commissioner, that paper trail is your most valuable asset.